Next Pep
In May 2025, the New England Journal of Medicine published the SURMOUNT-5 trial — the first randomised head-to-head comparison of tirzepatide (Zepbound) and semaglutide (Wegovy) in adults with obesity but without type 2 diabetes (NEJM, 2025). The result was clear: tirzepatide produced 47% greater relative weight loss. But what does that mean in practice, and who does it matter for?
Key Takeaways
- —Tirzepatide achieved −20.2% mean body weight loss vs −13.7% for semaglutide at 72 weeks (SURMOUNT-5, NEJM 2025).
- —31.6% of tirzepatide patients lost ≥25% body weight vs 16.1% on semaglutide.
- —Both drugs share similar GI-dominant side effect profiles; discontinuation rates were comparable.
- —Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide is a GLP-1 agonist only — the difference in mechanism may explain the efficacy gap.
- —Real-world 12-month data from a remote weight management programme mirrors trial results (PMC, 2026).
SURMOUNT-5 enrolled 751 adults with a BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and no type 2 diabetes. Patients were randomised 1:1 to maximum tolerated doses of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) over 72 weeks (Applied Clinical Trials, 2025).
The primary endpoint — least-squares mean percent change in body weight — showed:
| Metric | Tirzepatide | Semaglutide | Difference |
|---|---|---|---|
| Mean weight loss | −20.2% | −13.7% | −6.5 pp |
| ≥25% weight loss | 31.6% | 16.1% | ~2× more likely |
| Waist circumference | −18.4 cm | −13.0 cm | −5.4 cm |
The p-value was <0.001 across all primary and secondary endpoints. This is not a marginal result — it's a consistent, statistically robust separation across multiple outcome measures.
The mechanism difference matters. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide 1, which slows gastric emptying, increases satiety, and reduces food intake. It has demonstrated cardiovascular benefit and is approved for both diabetes (Ozempic) and obesity (Wegovy).
Tirzepatide adds a second mechanism: GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. GIP is typically thought of as a "fat storage" hormone, which made it a counterintuitive obesity target. But in combination with GLP-1 agonism, GIP agonism appears to enhance metabolic outcomes — including fat oxidation, adipose tissue remodeling, and insulin sensitivity — beyond what GLP-1 alone achieves.
<!-- [UNIQUE INSIGHT] The GIP paradox is one of the more interesting stories in metabolic pharmacology: a hormone classically associated with energy storage becomes, when combined with GLP-1 agonism, a driver of superior fat loss. The mechanism may involve GIP receptor signaling in adipose tissue that promotes lipolysis when GLP-1-mediated insulin is already suppressed — but this remains under active investigation. -->According to the SURMOUNT-5 investigators, the 47% greater relative weight loss with tirzepatide vs semaglutide — 20.2% vs 13.7% at 72 weeks — represents the largest efficacy gap observed in a head-to-head trial of approved anti-obesity medications to date (NEJM, 2025).
Trial populations are selected. Real-world data matters more for clinical decision-making. A 2026 retrospective study of patients in a remote weight management programme found tirzepatide users achieved greater weight reduction at 3 months (−2.4% additional), 6 months (−4.3% additional), and 12 months (−6.9% additional) compared to semaglutide (PMC, 2026). The real-world gap is directionally consistent with the trial data, though smaller in absolute magnitude — which is typical when moving from controlled trials to clinical practice.
A 2024 JAMA Internal Medicine study found tirzepatide patients were 76% more likely to achieve ≥5% weight loss, 154% more likely to achieve ≥10%, and 224% more likely to achieve ≥15% compared to semaglutide, based on real-world prescribing data.
Both drugs produce predominantly gastrointestinal adverse events: nausea, vomiting, diarrhoea, and constipation. In SURMOUNT-5, the side effect profiles were described as similar between arms, consistent with their shared GLP-1 mechanism. Discontinuation due to adverse events was comparable between groups.
The key tolerability difference in practice relates to titration. Both drugs require slow upward titration to minimise GI burden. Tirzepatide's weekly injection schedule is identical to semaglutide's. Neither has a clearly superior tolerability profile — the choice is primarily about efficacy targets, not side effect avoidance.
Not every patient is seeking 20% weight loss. For patients with a modest weight loss target (5–10%), semaglutide's established cardiovascular outcome data (SELECT trial, 2023) and longer track record may make it the more defensible clinical choice. For patients with obesity-related comorbidities who need substantial weight reduction — and for whom the 6.5 percentage point gap translates to clinically meaningful differences in joint load, sleep apnoea severity, or metabolic disease progression — tirzepatide's superior efficacy is relevant.
<!-- [UNIQUE INSIGHT] The clinical significance of a 6.5 pp difference in weight loss scales nonlinearly with starting BMI. A patient starting at 130 kg losing 20.2% loses approximately 26.3 kg; losing 13.7% loses 17.8 kg — a difference of 8.5 kg. At higher BMIs, this gap becomes the difference between achieving metabolic remission and remaining in a high-risk range. -->Both drugs face access barriers. List prices in the US exceed $1,000/month for both without insurance coverage. Tirzepatide's higher efficacy is accompanied by higher acquisition costs in most markets. The health economic calculus — whether superior weight loss translates to reduced downstream medical spending that justifies the cost differential — is actively being studied but not yet resolved.
Based on SURMOUNT-5 (NEJM, 2025), yes: tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks in adults with obesity without type 2 diabetes. Tirzepatide produced 47% greater relative weight loss.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. The addition of GIP agonism appears to enhance metabolic outcomes beyond GLP-1 alone, which may explain the efficacy difference.
Both produce predominantly gastrointestinal side effects (nausea, vomiting, diarrhoea). In head-to-head comparison, the overall side effect profiles were similar and discontinuation rates were comparable.
Semaglutide has more established cardiovascular outcome data from the SELECT trial (2023), which showed a 20% reduction in major adverse cardiovascular events in high-risk patients. Tirzepatide's cardiovascular outcome trial (SURPASS-CVOT) is ongoing.
This article is for research and informational purposes only. Both tirzepatide and semaglutide are prescription medications. Consult a licensed healthcare professional for personalised medical advice.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A 2025 systematic review of 544 studies found 35 preclinical and just 1 human BPC-157 trial. This guide covers mechanisms, precise pharmacokinetics, dosing protocols, and exactly what the human evidence shows.
TB-500 is a synthetic fragment of thymosin beta-4, studied for soft-tissue repair, anti-inflammatory effects, and cardiac recovery. Here's what the peer-reviewed literature shows.